Behavioral Health

Narcolepsy: diagnosis and treatment

Clinical Overview and When to Suspect Narcolepsy

— Narcolepsy type 1 (NT1): Excessive daytime sleepiness (EDS) plus cataplexy and/or low CSF orexin-A (<110 pg/mL). Strongly tied to HLA-DQB1*06:02 and post-H1N1/Pandemrix autoimmunity.

— Narcolepsy type 2 (NT2): EDS without cataplexy; normal orexin levels.

— Adolescent or young adult with daily irrepressible sleep attacks for ≥3 months despite adequate nighttime sleep

— Patient describes sudden bilateral muscle weakness triggered by laughter, surprise, or anger (cataplexy) — pathognomonic

— Sleep paralysis and hypnagogic/hypnopompic hallucinations on falling asleep or waking

— Disrupted nocturnal sleep paradoxically coexisting with EDS

— Recent motor vehicle accident from drowsy driving or workplace performance decline

Board pearl: A teenager with new-onset "fainting" when laughing who does NOT lose consciousness and recovers in seconds — that is cataplexy, not syncope or seizure. This single feature should anchor your differential toward NT1 and prompt referral for polysomnography with MSLT, not cardiology workup.

Step 3 management: Suspected narcolepsy is an outpatient sleep medicine referral — but first counsel against driving until diagnosis is clarified and treatment optimized.

Definition: Chronic neurologic disorder of sleep-wake regulation caused by loss of hypothalamic orexin (hypocretin) signaling, leading to intrusion of REM phenomena into wakefulness.

Two types per ICSD-3:

Epidemiology: Prevalence ~25–50 per 100,000. Bimodal onset peaks at ages 15 and 35. Often misdiagnosed for 8–15 years as depression, ADHD, or insufficient sleep.

When to suspect on Step 3:

Pentad to memorize: EDS, cataplexy, sleep paralysis, hypnagogic hallucinations, disrupted nighttime sleep. Only ~10% have all five.

Pathophysiology pearl: Selective destruction of ~70,000 orexin neurons in lateral hypothalamus, presumed autoimmune. Orexin normally stabilizes wakefulness and suppresses REM.

Presentation Patterns and Key History

— Irresistible sleep attacks lasting 10–20 minutes, often refreshing (distinct from idiopathic hypersomnia where naps are unrefreshing)

— Occur in monotonous AND active situations: driving, conversation, eating, mid-sentence

— Epworth Sleepiness Scale ≥10 (often 16–24) supports significant EDS

— "Automatic behaviors" — continues writing or driving with no recollection

— Sudden, bilateral, reversible loss of muscle tone with preserved consciousness

— Triggers: laughter (most specific), joking, anger, surprise, excitement

— Duration seconds to <2 minutes; partial forms = facial sagging, jaw drop, head nod, knee buckling, dysarthria

— Status cataplecticus can be precipitated by abrupt withdrawal of anticataplectic meds

Key distinction:

— Cataplexy = triggered by emotion, conscious, no postictal state, no incontinence

— Syncope = preceded by prodrome, brief LOC, no emotional trigger required

— Atonic seizure = LOC, postictal confusion, EEG abnormalities

— Conversion/functional = inconsistent, no stereotyped emotional trigger

Board pearl: Ask specifically: "Have you ever felt your knees buckle or jaw drop when laughing hard?" Patients rarely volunteer cataplexy because they normalize it. A positive answer is highly specific and shortcuts the workup.

Step 3 management: Document a sleep diary for 1–2 weeks plus actigraphy before MSLT to exclude insufficient sleep syndrome and shift work disorder, which can mimic narcolepsy on testing.

Excessive daytime sleepiness (cardinal symptom):

Cataplexy (defining feature of NT1):

Sleep paralysis: Inability to move at sleep-wake transitions, often with fear; lasts seconds to minutes.

Hypnagogic (falling asleep) / hypnopompic (waking) hallucinations: Vivid, often multimodal, frequently frightening — misdiagnosed as psychosis.

Disrupted nocturnal sleep: Frequent awakenings, vivid dreams, REM sleep behavior disorder in ~30%.

Comorbidities to screen: Obesity (orexin loss → metabolic effect), precocious puberty in pediatric NT1, depression, anxiety, ADHD-like inattention, migraine.

Physical Exam Findings and Objective Sleepiness Assessment

— Often unremarkable between events — narcolepsy is largely a history-based diagnosis

— May appear sleepy, yawning, with ptosis or head-bobbing during the encounter

— BMI frequently elevated, particularly in NT1 pediatric patients (rapid weight gain at symptom onset is a clue)

— Prompt patient to recall a funny memory or tell a joke — observe for facial flaccidity, jaw drop, neck flexion, tongue protrusion, knee buckling

— Loss of deep tendon reflexes during cataplectic attack (transient areflexia) — pathognomonic

— Patient remains awake and can answer questions with eye movements

— Should be normal between episodes — focal deficits suggest secondary (symptomatic) narcolepsy from hypothalamic lesion (tumor, MS, neuromyelitis optica, sarcoid, stroke, trauma, paraneoplastic anti-Ma2)

— Always check visual fields and cranial nerves; pituitary/hypothalamic mass can present this way

— Assess for OSA: neck circumference >17" (M)/16" (F), Mallampati III–IV, retrognathia — OSA frequently coexists and must be treated first

— Check for restless legs signs

— Epworth Sleepiness Scale (subjective, 0–24)

— Maintenance of Wakefulness Test (MWT) — used for occupational fitness-for-duty (pilots, commercial drivers), not diagnosis

— Pediatric: Pediatric Daytime Sleepiness Scale

Key distinction: A new focal neurologic finding (e.g., bitemporal hemianopsia, hemiparesis, ataxia) in a patient with EDS and cataplexy mandates brain MRI with pituitary protocol to exclude symptomatic narcolepsy before attributing symptoms to primary disease.

Board pearl: Transient areflexia during a laughter-induced episode captured on exam essentially clinches cataplexy and obviates extensive cardiac/seizure workup.

Step 3 management: Document baseline weight, BP, and mental status before initiating stimulants — these are your longitudinal monitoring anchors.

General appearance:

Witnessed cataplexy on exam (rare but powerful):

Neurologic exam baseline:

Sleep-related findings:

Objective sleepiness tools:

Diagnostic Workup — Initial Evaluation, Labs, and Screening

— Sleep diary ≥1–2 weeks plus wrist actigraphy to document ≥7 hours total sleep time

— Rules out insufficient sleep syndrome (most common EDS mimic) and shift work disorder — both can produce false-positive MSLT

— REM-suppressing drugs must be stopped ≥2 weeks (5 half-lives) before MSLT: SSRIs, SNRIs, TCAs, venlafaxine, fluoxetine (needs ~4–6 weeks), MAOIs

— Stop stimulants, sodium oxybate, modafinil ≥1–2 weeks prior

— Avoid alcohol, cannabis, opioids in the lead-up

— Urine drug screen on day of MSLT is standard to validate results

— TSH (hypothyroidism → hypersomnia)

— CBC, BMP, ferritin (anemia, iron deficiency contributing to RLS)

— HbA1c, fasting glucose (uncontrolled diabetes → fatigue)

— CMP, LFTs before stimulant initiation

— Pregnancy test in reproductive-age women

— HIV, RPR if risk factors (CNS infections cause symptomatic hypersomnia)

— Polysomnography evaluates AHI; OSA must be optimally treated before attributing residual EDS to narcolepsy

— Co-occurrence is common; residual sleepiness on adequate CPAP raises narcolepsy probability

— Brain MRI only if focal neuro findings, atypical age (>50), or rapid onset — to exclude hypothalamic mass, demyelination, paraneoplastic disease

Board pearl: A positive MSLT in a patient still on fluoxetine is invalid — REM rebound after SSRI withdrawal can also cause false positives, so timing matters.

Step 3 management: Order TSH, ferritin, sleep diary + actigraphy, and PSG before referring for MSLT — this is the standard outpatient narcolepsy pre-workup bundle.

Step 1 — Confirm adequate sleep opportunity:

Step 2 — Withdraw confounding medications:

Step 3 — Targeted labs to exclude mimics:

Step 4 — Screen for and treat OSA first:

Step 5 — Imaging if indicated:

HLA typing: HLA-DQB1*06:02 present in >95% of NT1 but ~25% of general population — high sensitivity, poor specificity; not diagnostic alone, useful adjunct.

Diagnostic Workup — Polysomnography, MSLT, and CSF Orexin

— Must document ≥6 hours total sleep

— Rules out OSA (AHI <5 or treated), periodic limb movement disorder, REM sleep behavior disorder

— Sleep-onset REM period (SOREMP) on PSG counts toward MSLT criteria (ICSD-3 update)

— 5 scheduled naps, 2 hours apart, beginning 1.5–3 hours after PSG awakening

— Each nap opportunity: 20 minutes

— Diagnostic criteria (ICSD-3):

– Mean sleep latency ≤8 minutes AND

– ≥2 SOREMPs across the PSG + MSLT (one nocturnal SOREMP within 15 min of sleep onset can substitute for one daytime SOREMP)

— <110 pg/mL (or <1/3 mean normal) = diagnostic of NT1 even without cataplexy

— Indications: equivocal MSLT, inability to withdraw REM-suppressing meds, atypical features

— Available at specialized centers

— NT1: EDS ≥3 months + (cataplexy AND positive MSLT) OR low CSF orexin

— NT2: EDS ≥3 months + positive MSLT + no cataplexy + normal orexin + not better explained by other cause

— MSLT less validated under age 6

— Cataplexy may present as "cataplectic facies" — tongue protrusion, ptosis, gait unsteadiness, hypotonia (status cataplecticus common at onset)

Key distinction:

— Narcolepsy: Mean latency ≤8 min, ≥2 SOREMPs, refreshing naps

— Idiopathic hypersomnia: Mean latency ≤8 min, <2 SOREMPs, long unrefreshing naps, prolonged nocturnal sleep (>11 hr)

— Insufficient sleep syndrome: Resolves with extended sleep on actigraphy

Board pearl: Two or more SOREMPs in someone off REM suppressants with documented adequate sleep is the MSLT fingerprint of narcolepsy — memorize "≤8 / ≥2."

Step 3 management: If CSF orexin <110 pg/mL, the diagnosis of NT1 is established even if MSLT is borderline — this is the rescue test for ambiguous cases.

Nocturnal polysomnography (PSG) — performed first, night before MSLT:

Multiple Sleep Latency Test (MSLT) — the diagnostic gold standard for sleepiness:

CSF orexin-A (hypocretin-1) measurement:

ICSD-3 diagnostic criteria summary:

Pediatric considerations:

Risk Stratification and First-Line Management Logic

— Restore daytime alertness sufficient for safe driving, school/work performance

— Suppress cataplexy and other REM intrusion phenomena

— Consolidate nocturnal sleep

— Manage comorbidities: obesity, depression, OSA

— Address psychosocial impact (school accommodations, disability paperwork, driving)

— Scheduled naps: 2–3 planned 15–20 minute naps daily — uniquely effective in narcolepsy

— Strict sleep hygiene: fixed bed/wake times including weekends

— Avoid alcohol (worsens fragmentation), heavy carbohydrate meals (postprandial sleepiness)

— Weight management, exercise

— Caffeine adjunct — not a substitute

— Driving safety counseling and state DMV reporting per local law

— EDS first-line: modafinil or armodafinil (wake-promoting agents)

— EDS alternatives/escalation: solriamfetol, pitolisant, methylphenidate, amphetamines

— Cataplexy first-line: sodium oxybate (or low-sodium oxybate) — also treats EDS and disrupted nocturnal sleep — or pitolisant

— Cataplexy alternatives: venlafaxine, fluoxetine, atomoxetine, clomipramine (off-label, used widely)

— Comorbid hypertension, cardiovascular disease → prefer solriamfetol cautiously, avoid amphetamines; low-sodium oxybate preferred over standard sodium oxybate

— History of substance use → pitolisant, solriamfetol preferred (lower abuse potential; pitolisant is non-scheduled)

— Depression with cataplexy → SNRI (venlafaxine) addresses both

— Pediatrics → sodium oxybate FDA-approved ≥7 years for cataplexy/EDS

Board pearl: Pitolisant (H3 inverse agonist) is the only non-scheduled narcolepsy medication — favored when abuse risk or controlled-substance access is a barrier.

Step 3 management: Always pair pharmacotherapy with scheduled naps and sleep hygiene — Step 3 questions reward the integrated answer over "just pick the drug."

Treatment goals (set with patient at diagnosis):

Non-pharmacologic foundation (always first, never sufficient alone):

Pharmacologic ladder by symptom target:

Risk stratification considerations:

Pharmacotherapy — First-Line Drug Regimens in Depth

— Mechanism: dopamine reuptake inhibition + downstream histamine/orexin effects

— Modafinil 100–400 mg AM (may split mid-morning + early afternoon); armodafinil 150–250 mg AM

— Adverse effects: headache, nausea, anxiety, insomnia, rare SJS/TEN, hypertension

— Reduces hormonal contraceptive efficacy — counsel on barrier or non-hormonal backup

— Schedule IV

— Dopamine-norepinephrine reuptake inhibitor; 75–150 mg AM

— Avoid in uncontrolled HTN, recent MI; monitor BP and HR

— Schedule IV; renal dose adjustment required

— Selective H3 inverse agonist → ↑ histamine release → wakefulness; also reduces cataplexy

— 8.9 → 17.8 → 35.6 mg AM titration over 3 weeks

— QT prolongation — avoid combining with other QT drugs; reduce dose in CYP2D6 poor metabolizers

— Not scheduled — major Step 3 talking point

— GHB salt; gold standard for cataplexy, also improves EDS and nocturnal sleep

— Dosed at bedtime AND 2.5–4 hours later (split dose) due to short half-life; once-nightly formulation (Lumryz) now available

— Adverse: respiratory depression (boxed warning), nausea, enuresis, parasomnias, abuse potential (Schedule III)

— REMS program; contraindicated with alcohol, sedatives, succinylcholine

— Choose low-sodium oxybate in HTN, HF, CKD — clinically meaningful sodium load reduction

— Reserved when first-line agents fail; Schedule II

— Monitor BP, HR, weight, mood, growth in pediatrics

— Venlafaxine 37.5–150 mg, fluoxetine, atomoxetine

— Never abruptly discontinue — risk of status cataplecticus

Board pearl: Modafinil + OCP failure = classic Step 3 trap. Always recommend non-hormonal contraception for 1 month after discontinuation.

Step 3 management: Start modafinil 200 mg AM + scheduled naps + sleep hygiene for typical EDS; add pitolisant or oxybate when cataplexy is prominent.

Modafinil / armodafinil (first-line for EDS):

Solriamfetol:

Pitolisant:

Sodium oxybate / low-sodium oxybate (Xyrem/Xywav):

Stimulants (methylphenidate, dextroamphetamine, mixed amphetamine salts):

Anticataplectics (when oxybate/pitolisant not used):

Expanded Pharmacology — Combinations, Titration, and Drug Interactions

— EDS + cataplexy often requires two agents: a wake-promoter (modafinil/solriamfetol/pitolisant) plus an anticataplectic (oxybate or SNRI)

— Pitolisant + oxybate combination is increasingly common — covers both axes

— Avoid stacking multiple QT-prolonging agents (pitolisant + ondansetron, macrolides, fluoroquinolones)

— Start low, titrate every 3–7 days based on Epworth, cataplexy frequency log, side effects

— Sodium oxybate: start 2.25 g × 2 nightly; titrate by 0.75 g/dose weekly to 6–9 g total

— Pitolisant: 8.9 → 17.8 → 35.6 mg over 3 weeks; effect may take up to 8 weeks

— Modafinil: 100 mg AM × 1 week → 200 mg → up to 400 mg split dosing

— Modafinil/armodafinil induces CYP3A4 → ↓ levels of OCPs, cyclosporine, midazolam, hormonal contraceptives, some HIV antiretrovirals

— Pitolisant induces CYP3A4 → similar OCP interaction; metabolized by CYP2D6 (dose reduce with paroxetine, fluoxetine)

— Sodium oxybate + CNS depressants/alcohol → fatal respiratory depression

— MAOIs + SNRI/TCA anticataplectics → serotonin syndrome; wash out 14 days

— Verify adherence and adequate dosing

— Reassess for untreated OSA (repeat PSG on therapy)

— Optimize sleep schedule and naps

— Try combination: e.g., oxybate at night + solriamfetol or pitolisant AM

— Consider referral to specialized sleep center; trials of orexin receptor agonists are emerging (not yet approved)

— Stimulants — monitor for dose escalation, diversion; use state PDMP at every refill

— Schedule narcolepsy patients for in-person follow-up every 3–6 months for controlled-substance prescribing

CCS pearl: In a CCS narcolepsy case, the optimal sequence is PSG → MSLT → start modafinil → add anticataplectic if cataplexy persists → schedule 3-month follow-up with Epworth re-administration and BP/weight check. Counsel driving safety at every visit.

Combination therapy principles:

Titration strategy:

Key drug interactions:

Refractory narcolepsy approach:

Tolerance and dependence:

Special Populations — Elderly and Renal/Hepatic Impairment

— New-onset narcolepsy after age 50 is rare — pursue brain MRI to exclude secondary causes (stroke, tumor, neurodegeneration, paraneoplastic)

— Always screen for and treat OSA, depression, hypothyroidism, polypharmacy-induced sedation before adding stimulants

— Anticholinergic burden from TCAs (clomipramine) → falls, cognitive decline, urinary retention — avoid in elderly

— Stimulants worsen pre-existing HTN, AF, ischemic heart disease — start at half-dose, monitor BP and ECG

— Sodium oxybate caution: increased fall risk on nocturnal awakenings (bathroom trips), prefer low-sodium oxybate given baseline CV/renal burden

— Solriamfetol: moderate CKD (eGFR 30–59) → max 75 mg; severe (15–29) → max 37.5 mg; ESRD → avoid

— Sodium oxybate: standard formulation delivers ~1100–1640 mg sodium per night — low-sodium oxybate strongly preferred in CKD, HTN, HF

— Pitolisant: no adjustment in mild-moderate; avoid in ESRD

— Modafinil: no specific renal adjustment, but limited data in severe CKD — use caution

— Modafinil: reduce dose by 50% in severe hepatic impairment

— Pitolisant: moderate hepatic impairment → max 17.8 mg; severe → contraindicated

— Sodium oxybate: metabolized hepatically → start at half dose

— Stimulants: generally hepatically metabolized; monitor LFTs at baseline and periodically

— Avoid amphetamines in significant CAD, uncontrolled HTN, structural heart disease, arrhythmias

— Baseline ECG before starting pitolisant (QT) or stimulants (HR, rhythm)

— Continue antihypertensives; recheck BP 2–4 weeks after any stimulant initiation or dose change

Key distinction: Low-sodium oxybate is not just a marketing variant — it removes ~1000–1500 mg sodium/night and is the guideline-preferred form in HTN, HF, and CKD per AASM.

Step 3 management: In any elderly patient with new EDS + cataplexy-like episodes, your first move is brain MRI, not MSLT — symptomatic narcolepsy must be excluded.

Elderly patients (>65):

Renal impairment:

Hepatic impairment:

Cardiovascular comorbidity:

Special Populations — Pregnancy, Pediatrics, and Comorbid Psychiatric Disease

— No narcolepsy medication is FDA Category A; risk-benefit must be individualized

— Many patients discontinue or reduce stimulants pre-conception and through first trimester; tolerate symptoms with scheduled naps and family/work accommodations

— Modafinil: signal for congenital malformations (cardiac, hypospadias, orofacial clefts) in pregnancy registry — avoid; counsel contraception

— Sodium oxybate: limited data; generally discontinued in pregnancy

— Cataplexy can worsen postpartum sleep deprivation — plan support

— Breastfeeding: stimulants and oxybate excreted in milk; discuss alternatives or formula

— Onset peak ~10–15 years; often follows H1N1 infection or (historically) Pandemrix vaccination

— Cataplexy in children may be atypical: persistent hypotonia, tongue protrusion, "cataplectic facies," gait ataxia — easily misdiagnosed as movement disorder or seizure

— Rapid weight gain and precocious puberty at symptom onset are characteristic

— School accommodations under IEP/504 plan: scheduled naps, extended testing time, late start

— Sodium oxybate FDA-approved age ≥7 for cataplexy/EDS; pitolisant approved for adults, expanding pediatric data; modafinil widely used off-label

— Monitor growth, BP, mood; stimulants can blunt growth velocity

— Depression prevalence ~30–50% — screen with PHQ-9 at each visit

— SNRIs (venlafaxine) can address depression and cataplexy simultaneously

— Avoid bupropion in seizure-prone patients; lowers threshold and rarely helpful for cataplexy

— ADHD overlap — stimulant therapy may treat both, but verify narcolepsy diagnosis first to avoid mislabeling

— Screen substance use given controlled-substance prescribing

Board pearl: A child with sudden weight gain, school failure, and "weak episodes when laughing" post-viral illness is the textbook pediatric NT1 stem — answer is sleep medicine referral for PSG/MSLT.

Step 3 management: Counsel effective non-hormonal contraception on every reproductive-age woman started on modafinil, armodafinil, or pitolisant — these induce CYP3A4 and reduce OCP efficacy for 1 month after discontinuation.

Pregnancy and lactation:

Pediatric narcolepsy:

Psychiatric comorbidity:

Complications and Adverse Outcomes

— Motor vehicle accidents: Narcolepsy patients have 3–10× higher MVA risk than general population — leading cause of morbidity/mortality

— Occupational injury and job loss — operating machinery, falls

— Academic underachievement in pediatric/adolescent patients

— Status cataplecticus: continuous or rapidly recurrent cataplexy, often triggered by abrupt SNRI/TCA withdrawal — medical emergency requiring re-initiation of anticataplectic

— REM sleep behavior disorder (acting out dreams) — injury to self/bed partner

— Obesity and metabolic syndrome — orexin loss predisposes; compounded by sedentary behavior

— Depression, anxiety, social isolation — suicide risk elevated

— Modafinil/armodafinil: Stevens-Johnson syndrome/TEN (rare but serious — stop at first rash), psychiatric symptoms (mania, psychosis, suicidality), HTN

— Stimulants: appetite suppression, growth suppression in children, HTN, tachyarrhythmias, psychosis, dependence/diversion

— Sodium oxybate: respiratory depression (especially with alcohol, opioids, benzodiazepines — fatal interactions reported), parasomnias including sleepwalking, enuresis, depression/suicidality, abuse potential ("date-rape drug" GHB)

— Pitolisant: QT prolongation, insomnia, headache, OCP failure

— Solriamfetol: dose-dependent BP/HR elevation, anxiety

— SNRI/TCA withdrawal: rebound cataplexy

— Annual lipid panel, fasting glucose/HbA1c, weight, BP

— ECG before pitolisant; periodic on stimulants

— DEXA not routinely indicated unless other risk factors

Key distinction: Status cataplecticus vs. serotonin syndrome — both can occur in narcolepsy on SNRIs. Status cataplecticus = recurrent atonia with preserved consciousness, no autonomic instability; serotonin syndrome = hyperthermia, clonus, autonomic chaos, altered mental status.

Board pearl: Concomitant alcohol or opioids with sodium oxybate is a boxed warning and a classic Step 3 "what's the most likely cause of death" stem — respiratory depression.

Step 3 management: Counsel patients to never abruptly stop anticataplectic medication; taper over weeks under supervision.

Disease-related complications:

Treatment-related complications:

Long-term metabolic and CV monitoring:

When to Escalate — Inpatient, Consult, and Urgent Triage

— Suspected narcolepsy in any patient (primary care should refer for MSLT)

— Refractory EDS despite first-line therapy

— Diagnostic ambiguity — atypical MSLT, normal HLA in suspected NT1

— Pediatric narcolepsy — pediatric sleep specialist preferred

— Need for CSF orexin measurement

— Focal neurologic findings → workup for symptomatic narcolepsy (MS, tumor, paraneoplastic anti-Ma2, NMO)

— Atypical cataplexy mimics (seizure, syncope, drop attacks) → EEG, tilt-table, cardiac workup

— Status cataplecticus refractory to oral therapy

— Co-occurring severe depression with suicidality

— Psychosis emerging on stimulant or modafinil

— Substance use disorder complicating controlled-substance prescribing

— Sodium oxybate overdose or co-ingestion with alcohol/opioids → ICU for airway monitoring; reversal is supportive (no specific antidote; flumazenil not effective)

— Stevens-Johnson syndrome on modafinil → burn unit/ICU

— Severe stimulant toxicity → hypertensive crisis, arrhythmia, hyperthermia → ICU, benzodiazepines, cooling, avoid pure beta-blockade (unopposed alpha)

— Status cataplecticus with airway compromise or aspiration risk

— Suicidality on narcolepsy medications

— Significant BP/HR rise on stimulants or solriamfetol

— New QT prolongation on pitolisant

— Pre-existing structural heart disease requiring drug class decisions

CCS pearl: In a CCS case of suspected sodium oxybate overdose, order ABG, intubate for GCS ≤8 or hypoventilation, place on telemetry, support BP, avoid flumazenil/naloxone (ineffective), monitor in ICU until oxybate clears (~4–8 hours). Counsel REMS-compliance and screen for intentional overdose.

Step 3 management: Any narcolepsy patient with new psychosis, mania, or suicidal ideation on therapy requires immediate medication review and psychiatric evaluation — do not simply "continue and observe."

Indications for sleep medicine consultation/referral:

Neurology consultation:

Psychiatric consultation:

Inpatient admission scenarios (uncommon but high-yield):

Cardiology consultation:

Key Differentials — Other Hypersomnia Disorders

— EDS, long unrefreshing naps (often >1 hour), prolonged nocturnal sleep (>11 hours), severe sleep inertia / "sleep drunkenness" on waking

— MSLT: mean latency ≤8 min but <2 SOREMPs (key discriminator)

— Treatment: modafinil, low-sodium oxybate (FDA-approved), pitolisant (off-label)

— Adolescent males; episodic hypersomnia (days–weeks) with hyperphagia, hypersexuality, derealization, cognitive changes

— Asymptomatic between episodes

— Lithium or stimulants during episodes; self-limited over years

— Most common cause of EDS; resolves with adequate sleep extension

— Confirmed by actigraphy/diary showing chronic short sleep

— Loud snoring, witnessed apneas, obesity, morning headaches, nocturia

— PSG: AHI ≥5 with symptoms or ≥15

— Treat with CPAP; persistent sleepiness despite optimal CPAP raises narcolepsy probability

— Delayed sleep phase (adolescents), shift work disorder, jet lag

— Sleep diary/actigraphy diagnostic; treated with timed light, melatonin, schedule shift

— Fragmented sleep with daytime sleepiness; check ferritin, treat iron deficiency, dopamine agonists or alpha-2-delta ligands

— Sedating antihistamines, opioids, benzodiazepines, antipsychotics, alcohol, cannabis

— Review medication list before any sleep study

Key distinction:

— Narcolepsy: Short refreshing naps, REM intrusion, MSLT ≤8 min + ≥2 SOREMPs

— Idiopathic hypersomnia: Long unrefreshing naps, severe sleep inertia, long nocturnal sleep, <2 SOREMPs

— OSA: Snoring/apneas, AHI elevated, resolves with CPAP

— Kleine-Levin: Episodic with behavioral changes, normal between

Board pearl: "Long unrefreshing naps + sleep drunkenness + 12-hour nocturnal sleep + 1 SOREMP on MSLT" = idiopathic hypersomnia, not narcolepsy. The SOREMP count and nap quality are your decision points.

Step 3 management: Always treat OSA first in patients with mixed picture; reassess for residual sleepiness 3 months into adherent CPAP before pursuing narcolepsy workup.

Idiopathic hypersomnia (IH):

Kleine-Levin syndrome:

Insufficient sleep syndrome:

Obstructive sleep apnea:

Circadian rhythm disorders:

Restless legs / periodic limb movement disorder:

Medication/substance-induced hypersomnia:

Key Differentials — Other-Category Mimics

— Loss of consciousness, often preceded by lightheadedness or palpitations

— Triggers: exertion, posture change, arrhythmia

— Workup: ECG, echo, Holter/event monitor, tilt-table

— Cataplexy: consciousness preserved, emotion-triggered, no prodrome

— Sudden loss of tone with impaired consciousness, possible incontinence, postictal confusion

— EEG abnormalities; MRI may show structural lesion

— Distinguished from cataplexy by EEG and absence of emotional trigger

— Older patients, vascular risk factors, focal neurologic features

— Carotid/vertebrobasilar imaging

— Inconsistent triggers, variable exam, often follows psychosocial stressor

— Normal PSG/MSLT

— Genetic glycine receptor disorder; exaggerated startle with stiffness (not atonia)

— Onset in infancy; responds to clonazepam

— Major depression with atypical features — hypersomnia, hyperphagia, leaden paralysis

— Bipolar depression

— Anxiety with sleep-onset insomnia → daytime fatigue

— These rarely produce true sleep attacks or cataplexy

— Hypothyroidism, Cushing's, hyponatremia, hypercalcemia, B12 deficiency, hepatic encephalopathy

— Targeted labs at initial workup

— Parkinson disease (EDS common), Lewy body dementia, myotonic dystrophy

— Age, exam, and history distinguish

— Hypothalamic lesions: craniopharyngioma, sarcoid, MS, NMO, paraneoplastic anti-Ma2, traumatic brain injury, Niemann-Pick type C, Prader-Willi

— MRI mandatory in atypical presentations

Key distinction: Cataplexy ≠ syncope ≠ atonic seizure. Consciousness preserved + emotional trigger + transient areflexia = cataplexy. Memorize this triad.

Board pearl: Anti-Ma2 paraneoplastic encephalitis (often testicular germ cell tumor) can present with narcolepsy-cataplexy + hypothalamic dysfunction — image and screen for malignancy in atypical adult-onset cases.

Step 3 management: In adult-onset narcolepsy with atypical features, order brain MRI + paraneoplastic panel + testicular exam/ultrasound before committing to primary narcolepsy diagnosis.

Cardiogenic syncope (vs. cataplexy):

Atonic seizures and other epilepsies:

Transient ischemic attack / drop attacks:

Conversion disorder / functional neurologic symptom disorder:

Hyperekplexia (startle disease):

Psychiatric mimics of EDS:

Endocrine and metabolic:

Neurodegenerative:

Secondary (symptomatic) narcolepsy:

Long-Term Plan, Secondary Prevention, and Maintenance Medications

— Narcolepsy is chronic and currently incurable; treatment is symptomatic

— Discuss with patient and family at diagnosis; provide written summary and reliable resources (Narcolepsy Network, Wake Up Narcolepsy)

— Most patients require combination therapy indefinitely

— Periodic re-titration as symptoms, weight, and comorbidities evolve

— Annual review of indication, dose, side effects, controlled-substance agreement

— Annual BP, lipid panel, fasting glucose/HbA1c, BMI

— Treat HTN to standard targets (ACC/AHA <130/80 in most adults with elevated risk)

— Statin per ASCVD risk

— Weight management — narcolepsy patients have elevated obesity prevalence even normalized for activity

— Smoking cessation counseling at every visit

— Annual influenza, COVID boosters, age-appropriate adult vaccines

— Cancer screening per USPSTF (colon, cervical, breast, lung, prostate as indicated)

— Depression screening (PHQ-9) at minimum annually

— Scheduled naps, sleep schedule consistency

— Alcohol moderation (especially if on oxybate — absolute avoidance)

— Driving safety reassessment annually or with symptom change

— Pre-conception counseling: medication review, contraception until plan in place

— Most stimulants/oxybate discontinued during pregnancy

— IEP/504 plans for students

— ADA accommodations at workplace: scheduled break for napping, flexible hours, avoid safety-sensitive shift work

— Disability paperwork support when indicated

— State PDMP query at each prescription

— Written controlled-substance agreement

— In-person visits every 3–6 months minimum

Board pearl: Treat OSA and hypertension aggressively in narcolepsy — these are modifiable contributors to both daytime sleepiness and cardiovascular morbidity, which is elevated in this population.

Step 3 management: Document annual driving safety counseling and MVA history in the chart — this is both a quality measure and medicolegal protection.

Lifelong disease — set expectations early:

Maintenance pharmacotherapy:

Cardiometabolic risk reduction (Step 3-flavored secondary prevention):

Vaccinations and preventive care:

Behavioral pillars (reinforce at every visit):

Pregnancy planning:

School/work accommodations:

Controlled-substance stewardship:

Follow-Up, Monitoring Parameters, and Counseling

— 2–4 weeks after starting or adjusting medication: tolerability, side effects, BP/HR check

— 3 months: symptom response (Epworth, cataplexy diary), dose optimization

— Every 3–6 months thereafter for controlled-substance prescribing and stable patients

— Annual comprehensive review: comorbidities, mental health, driving, occupational status

— Epworth Sleepiness Scale at every visit — goal <10 or patient-defined improvement

— Cataplexy frequency diary — events per week, triggers, severity

— Functional Outcomes of Sleep Questionnaire (FOSQ) for quality of life

— Sleep diary if treatment response stalls

— Modafinil/armodafinil: BP, HR, mood, rash (stop immediately if rash), pregnancy testing if reproductive-age

— Solriamfetol: BP, HR (baseline and follow-up); renal function

— Pitolisant: ECG (QTc) at baseline and after titration; LFTs periodically

— Sodium oxybate: BP, weight, depression/suicidality screen, parasomnia review; sodium load in low-sodium formulation

— Stimulants: BP, HR, weight (growth in children), mental status, signs of misuse

— SNRIs/TCAs: mood, BP, ECG (TCAs), sexual side effects, withdrawal risk

— Document conversation

— Advise against driving until adequate symptom control demonstrated (typically 3+ months stable on therapy)

— Recommend short trips, daytime only, scheduled prophylactic naps before driving

— MWT may be required for commercial drivers per DOT/state DMV

— Cognitive behavioral approaches for narcolepsy (CBT-N) — emerging evidence for fatigue, mood, adherence

— Support groups, peer connection

— Exercise prescription — improves wakefulness and weight

— Repeat PSG/MSLT generally not needed unless diagnosis questioned or for occupational certification (MWT)

Board pearl: Repeat MWT is the test of choice for commercial driver fitness-for-duty, not MSLT — MWT measures ability to stay awake, which is the safety-relevant endpoint.

Step 3 management: At every visit, re-administer Epworth, query cataplexy frequency, check BP/HR, and document driving counseling — this is the standard narcolepsy maintenance bundle.

Follow-up cadence:

Symptom tracking tools:

Monitoring parameters by medication:

Driving counseling (every visit):

Rehab and lifestyle counseling:

Re-testing:

Ethical, Legal, and Patient Safety Considerations

— State laws vary on physician reporting of impaired drivers — some mandatory (e.g., California, Pennsylvania, Oregon), most permissive

— Document the conversation, recommendations, and patient's stated compliance at every visit

— In states without mandatory reporting, physicians may still report under permissive statutes if patient continues unsafe driving — this generally overrides confidentiality under Tarasoff-like duty-to-protect doctrines

— Commercial drivers (CDL) fall under DOT regulations: narcolepsy is a disqualifying condition unless waiver granted with documented stability and MWT performance

— Counsel against safety-sensitive work (heavy machinery, aviation, surgery, electrical) until controlled

— Pilots: FAA disqualification; some waivers possible with demonstrated control

— ADA-protected disability — employers must provide reasonable accommodations (nap breaks, schedule flexibility) but not at the expense of safety-sensitive duties

— Written agreement, single-prescriber/single-pharmacy model, PDMP at each refill

— Diversion risk especially with stimulants and oxybate (GHB)

— REMS program required for sodium oxybate prescribing

— Adolescents on stimulants/oxybate: involve guardian; discuss abuse potential, contraception, school disclosure

— Sodium oxybate REMS requires documented patient education on abuse, alcohol/sedative interaction, and overdose risk before dispensing

— Modafinil and contraception: documented counseling about reduced OCP efficacy is a medicolegal must

— Patients leaving pediatric to adult sleep clinics, college transitions, military service, or insurance changes are at high risk for medication gaps → status cataplecticus or MVA

— Arrange warm handoff, 90-day medication supply when possible, and patient self-advocacy training

— Narcolepsy is often dismissed as laziness — validate, provide diagnosis documentation for school/employer

— Screen for and treat depression; elevated suicide risk

Board pearl: A patient with poorly controlled narcolepsy who continues to drive against medical advice triggers a duty-to-protect analysis: counsel, document, escalate to DMV reporting under permissive/mandatory state law — patient confidentiality yields to public safety.

Step 3 management: At hospital discharge or clinic transition, explicitly schedule the next sleep medicine follow-up and confirm 30-day medication supply — preventing the lapse is the safety intervention.

Driving safety and DMV reporting:

Occupational safety:

Controlled-substance ethics:

Informed consent edge cases:

Transition of care risk (Step 3 hallmark):

Stigma and mental health:

High-Yield Associations and Rapid-Fire Clinical Facts

— HLA-DQB1*06:02 present in >95% of NT1 (sensitive, not specific)

— Autoimmune mechanism: T-cell-mediated destruction of orexin neurons

— H1N1 (2009) infection and Pandemrix vaccination (Europe only) linked to surge in pediatric NT1

— Family history positive in <10% — sporadic in most

— Orexin (hypocretin)-A and -B from lateral hypothalamus stabilize wakefulness, suppress REM

— Loss of ~70,000 orexin neurons → REM dysregulation

— CSF orexin <110 pg/mL diagnostic of NT1

— MSLT: mean sleep latency ≤8 min + ≥2 SOREMPs

— Adequate sleep on PSG: ≥6 hours

— Symptom duration: ≥3 months

— REM suppressant washout: ≥2 weeks (fluoxetine 4–6 weeks)

— Modafinil — Schedule IV, CYP3A4 inducer, OCP failure

— Pitolisant — non-scheduled, H3 inverse agonist, QT prolongation

— Solriamfetol — Schedule IV, DNRI, renal dose

— Sodium oxybate — Schedule III, REMS, split nightly dosing, respiratory depression with alcohol

— Low-sodium oxybate — preferred in HTN/HF/CKD

— Obesity, depression, OSA, REM behavior disorder, precocious puberty (pediatric NT1), migraine

— Tongue protrusion, cataplectic facies, gait unsteadiness, sudden weight gain post-viral illness

— Idiopathic hypersomnia: long unrefreshing naps, <2 SOREMPs

— OSA: snoring, AHI elevated, CPAP-responsive

— Kleine-Levin: episodic, behavioral changes

— Modafinil + OCP → contraceptive failure

— Sodium oxybate + alcohol/opioids → fatal apnea

— Abrupt SNRI/TCA stop → status cataplecticus

Board pearl: "Adolescent, daily sleep attacks, knees buckle when laughing, vivid hallucinations when falling asleep" = NT1 — answer is PSG followed by MSLT after sleep diary documents adequate sleep and REM suppressants are stopped.

Step 3 management: When you see narcolepsy on the exam, immediately check the medication list for SSRIs, the sleep diary, and the patient's driving status — these are the high-yield distractors and decision drivers.

Genetics and immunology:

Neurobiology:

Diagnostic numbers to memorize:

Drug class quick-fire:

Comorbidities:

Pediatric clues:

Mimics to distinguish:

Pharmacology traps:

Board Question Stem Patterns

— 17-year-old with 6 months of irresistible daytime sleep, "fainting when laughing," vivid images on falling asleep

— Answer: PSG + MSLT (after sleep diary and SSRI washout)

— Trap: choosing EEG (not seizure), tilt-table (not syncope), or empiric stimulant

— Young woman started on modafinil for narcolepsy, now pregnant despite OCP use

— Answer: Modafinil induces CYP3A4 → reduced OCP efficacy; counsel non-hormonal contraception for 1 month after discontinuation

— Narcolepsy patient found unresponsive at home with empty wine bottle and Xyrem

— Answer: Airway management and supportive ICU care; flumazenil and naloxone ineffective; no specific antidote

— Patient with NT1 abruptly stopped venlafaxine, now with continuous bilateral weakness episodes

— Answer: Re-initiate anticataplectic; never abruptly discontinue

— 55-year-old new-onset EDS with cataplexy, bitemporal hemianopsia, headaches

— Answer: Brain MRI before MSLT — exclude craniopharyngioma/hypothalamic lesion

— Patient with long unrefreshing naps, 12-hour nocturnal sleep, sleep drunkenness, MSLT shows mean latency 6 min with 1 SOREMP

— Answer: Idiopathic hypersomnia, not narcolepsy

— Obese man with EDS, AHI 35, witnessed apneas, asks if he has narcolepsy

— Answer: Treat OSA with CPAP first; reassess at 3 months

— Child with rapid weight gain, school failure, tongue protrusion, knee buckling after H1N1 infection

— Answer: Pediatric sleep referral for PSG/MSLT; HLA-DQB1*06:02 supportive

— Narcolepsy patient discloses 2 MVAs in past year, continues to drive

— Answer: Counsel cessation, optimize therapy, report to DMV per state law (mandatory or permissive)

— Patient with narcolepsy and history of stimulant misuse needs EDS therapy

— Answer: Pitolisant — only non-scheduled narcolepsy drug

Board pearl: When the stem includes age >50, focal exam findings, or rapid onset, pivot to MRI before MSLT — secondary narcolepsy must be excluded.

Stem pattern 1 — Classic NT1:

Stem pattern 2 — Modafinil + OCP:

Stem pattern 3 — Sodium oxybate overdose:

Stem pattern 4 — Status cataplecticus:

Stem pattern 5 — Symptomatic narcolepsy:

Stem pattern 6 — Distinguishing from idiopathic hypersomnia:

Stem pattern 7 — OSA precedence:

Stem pattern 8 — Pediatric NT1 post-H1N1:

Stem pattern 9 — Driving safety:

Stem pattern 10 — Pitolisant selection:

One-Line Recap

Narcolepsy is a chronic orexin-deficiency sleep-wake disorder diagnosed by ≥3 months of EDS plus either cataplexy with confirmatory MSLT (mean sleep latency ≤8 min, ≥2 SOREMPs) or low CSF orexin, and managed lifelong with scheduled naps plus stage-tailored pharmacotherapy (wake-promoters like modafinil/pitolisant/solriamfetol for EDS, sodium oxybate or pitolisant or SNRIs for cataplexy), aggressive driving-safety counseling, and treatment of comorbid OSA, depression, and metabolic disease.

Board pearl: The single most testable narcolepsy fact is the MSLT rule (≤8 / ≥2 SOREMPs) combined with cataplexy = preserved consciousness with emotion-triggered bilateral atonia — master these two anchors and the rest of the topic falls into place on Step 3.

Diagnose: Sleep diary + actigraphy → withdraw REM suppressants ≥2 weeks → PSG (≥6 h sleep) → MSLT: ≤8 min mean latency + ≥2 SOREMPs → CSF orexin <110 pg/mL if equivocal. Atypical or late onset → brain MRI first to exclude symptomatic narcolepsy.

Treat EDS: Modafinil/armodafinil first-line (counsel OCP failure); solriamfetol or pitolisant alternatives (pitolisant = only non-scheduled option, watch QT); stimulants reserved for refractory cases. Always pair with scheduled 15–20 minute naps and strict sleep hygiene.

Treat cataplexy: Sodium oxybate (low-sodium preferred in HTN/HF/CKD) or pitolisant first-line; SNRIs/TCAs second-line. Never abruptly discontinue — status cataplecticus risk. Oxybate + alcohol/opioids = fatal respiratory depression.

Follow up and protect: Re-administer Epworth, log cataplexy events, check BP/HR, screen depression at every visit; document driving counseling and report to DMV per state law if unsafe; ensure 90-day medication continuity at care transitions; treat OSA, depression, and cardiometabolic risk aggressively.